循環器ジャーナル66巻1号

2018年01月発行

特集 循環器診療　薬のギモン—エキスパートに学ぶ薬物治療のテクニック Ⅰ．心不全診療でのギモン

投与中の心筋保護薬．やめたらどうなるの？

著者： 奥村貴裕¹

所属機関： ¹名古屋大学大学院医学系研究科循環器内科学

ページ範囲：P.30 - P.38

Point
・左室駆出率の低下した心不全では，ACE阻害薬・ARB，β遮断薬，ミネラルコルチコイド受容体拮抗薬といった心筋保護薬の有用性が確立している．
・心不全の急性増悪入院では，可能な限り，心筋保護薬を中止しない．
・左室駆出率が改善した心不全においても心筋保護薬継続が望ましいとされるが，心臓原疾患によって要否が異なる可能性がある．

参考文献

1) Ponikowski P, Voors AA, Anker SD, et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology（ESC）Developed with the special contribution of the Heart Failure Association（HFA）of the ESC. Eur Heart J 37:2129-2200, 2016

2) Nijst P, Martens P, Mullens W:Heart failure with Myocardial Recovery-The Patient Whose Heart Failure Has Improved:What Next? Prog Cardiovasc Dis, 2017［Epub ahead of print］

3) CONSENSUS Trial Study Group:Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study（CONSENSUS）. N Engl J Med 316:1429-1435, 1987

4) Matsumori A;Assessment of Response to Candesartan in Heart Failure in Japan（ARCH-J）Study Investigators:Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5:669-677, 2003

5) Packer M, Coats AJ, Fowler MB, et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

6) Pitt B, Zannad F, Remme WJ, et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999

7) Kane JA, Kim JK, Haidry SA, et al:Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction. Cardiology 137:121-125, 2017

8) Gilstrap LG, Fonarow GC, Desai AS, et al:Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc 6:e004675, 2017

9) Fonarow GC, Abraham WT, Albert NM, et al:Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure:findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52:190-199, 2008

10) Butler J, Young JB, Abraham WT, et al:Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 47:2462-2469, 2006

11) Metra M, Torp-Pedersen C, Cleland JG, et al:Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 9:901-909, 2007

12) Orso F, Baldasseroni S, Fabbri G, et al:Role of beta-blockers in patients admitted for worsening heart failure in a real world setting:data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail 11:77-84, 2009

13) MiróÒ, Müller C, Martín-Sánchez FJ, et al:BETAWIN-AHF study:effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure. Clin Res Cardiol 105:1021-1029, 2016

14) Jondeau G, Neuder Y, Eicher JC, et al:B-CONVINCED:Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 30:2186-2192, 2009

15) 奥村貴裕：急性心不全治療におけるPDEⅢ阻害薬の使い方．循環器ジャーナル　第65巻第1号〔加藤真帆人(編)〕，医学書院，東京，pp100-107，2017

16) Parameswaran AC, Tang WH, Francis GS, et al:Why do patients fail to receive beta-blockers for chronic heart failure over time? A ” real-world” single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure. Am Heart J 149:921-926, 2005

17) Punnoose LR, Givertz MM, Lewis EF, et al:Heart failure with recovered ejection fraction:a distinct clinical entity. J Card Fail 17:527-532, 2011

18) Basuray A, French B, Ky B, et al:Heart failure with recovered ejection fraction:clinical description, biomarkers, and outcomes. Circulation 129:2380-2387, 2014

19) Lupón J, Díez-López C, de Antonio M, et al:Recovered heart failure with reduced ejection fraction and outcomes:a prospective study. Eur J Heart Fail, 2017［Epub ahead of print］

20) Moon J, Ko YG, Chung N, et al:Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 25:e147-e150, 2009

21) Hopper I, Samuel R, Hayward C, et al:Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. J Card Fail 20:522-532, 2014

22) Basuray A, Fang JC:Management of Patients With Recovered Systolic Function. Prog Cardiovasc Dis 58:434-443, 2016